University of Pennsylvania
Wynnewood, PA, United States
Dr. Victoria Werth is a Professor of Dermatology and Medicine at the University of Pennsylvania School of Medicine and Chief of the Division of Dermatology at the Philadelphia Veterans Administration Hospital. Dr. Werth earned her medical degree from Johns Hopkins University School of Medicine in Baltimore, Maryland. She completed a residency in internal medicine at Northwestern Memorial Hospital in Chicago, Illinois, and dermatology residency and immunodermatology fellowship at New York University School of Medicine in New York. She joined the faculty at Penn in 1989 and has developed an internationally recognized program in autoimmune skin diseases.
Sunday, November 12, 2023
9:00 AM – 11:00 AM PT
Disclosure(s): AbbVie: Consultant (Terminated, March 17, 2022); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); Anaptysbio: Consultant (Ongoing); Argenx: Grant/Research Support (Ongoing); AstraZeneca: Consultant (Ongoing); Biogen: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol Myers Squibb: Consultant (Ongoing); Celgene: Consultant (Terminated, October 21, 2021), Grant/Research Support (Terminated, October 21, 2021); Corbus: Grant/Research Support (Terminated, January 11, 2021); CSL Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); EMD Serono: Consultant (Ongoing); Galderma: Consultant (Ongoing); Genentech: Grant/Research Support (Ongoing); Gilead: Consultant (Ongoing), Grant/Research Support (Ongoing); GlaxoSmithKline: Consultant (Ongoing); Horizon Therapeutics: Grant/Research Support (Ongoing); Idera: Consultant (Ongoing); Incyte: Consultant (Ongoing); Janssen: Consultant (Ongoing); Kyowa Kirin: Consultant (Ongoing); Lilly: Consultant (Ongoing); MedImmune: Consultant (Ongoing); Medscape: Consultant (Ongoing); Merck: Consultant (Ongoing); Nektar: Consultant (Ongoing); Novartis: Consultant (Ongoing); Octapharma: Consultant (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Principia: Consultant (Ongoing); Regeneron: Grant/Research Support (Ongoing); Resolve: Consultant (Ongoing), Consultant (Ongoing); Rome Therapeutics: Consultant (Ongoing), Grant/Research Support (Ongoing); Sanofi: Consultant (Ongoing); Ventus: Grant/Research Support (Ongoing); Viela: Consultant (Terminated, May 6, 2022), Grant/Research Support (Terminated, May 6, 2022); Xencor: Consultant (Ongoing)
Meet the Panel: Challenging Cases in Adult and Juvenile Myositis
Sunday, November 12, 2023
2:00 PM – 2:45 PM PT
Disclosure(s): AbbVie: Consultant (Terminated, March 17, 2022); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); Anaptysbio: Consultant (Ongoing); Argenx: Grant/Research Support (Ongoing); AstraZeneca: Consultant (Ongoing); Biogen: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol Myers Squibb: Consultant (Ongoing); Celgene: Consultant (Terminated, October 21, 2021), Grant/Research Support (Terminated, October 21, 2021); Corbus: Grant/Research Support (Terminated, January 11, 2021); CSL Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); EMD Serono: Consultant (Ongoing); Galderma: Consultant (Ongoing); Genentech: Grant/Research Support (Ongoing); Gilead: Consultant (Ongoing), Grant/Research Support (Ongoing); GlaxoSmithKline: Consultant (Ongoing); Horizon Therapeutics: Grant/Research Support (Ongoing); Idera: Consultant (Ongoing); Incyte: Consultant (Ongoing); Janssen: Consultant (Ongoing); Kyowa Kirin: Consultant (Ongoing); Lilly: Consultant (Ongoing); MedImmune: Consultant (Ongoing); Medscape: Consultant (Ongoing); Merck: Consultant (Ongoing); Nektar: Consultant (Ongoing); Novartis: Consultant (Ongoing); Octapharma: Consultant (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Principia: Consultant (Ongoing); Regeneron: Grant/Research Support (Ongoing); Resolve: Consultant (Ongoing), Consultant (Ongoing); Rome Therapeutics: Consultant (Ongoing), Grant/Research Support (Ongoing); Sanofi: Consultant (Ongoing); Ventus: Grant/Research Support (Ongoing); Viela: Consultant (Terminated, May 6, 2022), Grant/Research Support (Terminated, May 6, 2022); Xencor: Consultant (Ongoing)